ADCT, CRT indication agreements to develop ADCs against cancer Cancer Analysis Technology , the commercial arm of Cancer Analysis UK, and Switzerland-structured ADC Therapeutics Sarl announce today they have signed agreements to develop cancer treatments called Antibody Medication Conjugates using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries levitra . ADCs are a thrilling and important course of oncology drugs as clinically they combine the specificity of antibodies with novel ‘warhead’ chemistries. The antibody component targets the cancers cells to deliver tumour-destroying chemicals which are internalised in to the cancer tumor cell while avoiding damage to healthy tissue.